On the other hand, inhibitors of the DPP-IV enzyme are used in the treatment of diabetes because they increase the half-life of incretins [9], which are peptide hormones that stimulate more than 50% of insulin secretion, especially the hormone glucagon peptide (GLP-1) [10]. The gene discussed is INS; the disease is diabetes mellitus.